Table 3. Univariate and multivariate analysis of disease-free survival rate for HCC in cohort 1.

	Univariate			Multivariate
	HR	95% CI	P	HR	95% CI	P
Sex
Female	1
Male	0.989	0.620–1.579	0.965
Age (years)
<55	1
≥55	1.200	0.820–1.755	0.349
Etiology
Non-viral	1
Viral	0.939	0.536–1.645	0.825
Cirrhosis
Absent	1			1
Present	1.859	1.251–2.761	0.002	1.815	1.208–2.729	0.004
Tumor size (cm)
<5	1			1
≥5	1.977	1.309–2.986	0.001	1.533	0.952–2.468	0.079
Edmondson grade
I/II	1			1
III/IV	1.685	1.150–2.469	0.007	1.186	0.779–1.804	0.427
Vascular invasion
Absent	1			1
Present	2.179	1.437–3.302	<0.001	1.764	1.118–2.784	0.015
Multiplicity
Single	1			1
Multiple	2.250	1.470–3.445	<0.001	1.399	0.787–2.488	0.253
Stage (by AJCC)
I–II	1			1
III–IV	4.652	2.636–8.211	<0.001	2.214	0.921–4.898	0.077
Fibrous stroma
Not abundant	1
Abundant	0.931	0.548–1.581	0.790
K19 expression
Negative	1
Positive	0.952	0.609–1.487	0.828
CCN2 expression
Negative	1			1
Positive	1.886	1.207–2.948	0.005	1.561	0.989–2.465	0.056
EMA expression
Negative	1
Positive	0.782	0.460–1.329	0.363
FAP expression
Negative	1
Positive	0.617	0.252–1.515	0.292

HCC, Hepatocellular carcinoma; CCN2, Connective tissue growth factor; EMA, Epithelial membrane antigen; FAP, Fibroblast activation protein.